Ollin Biosciences
Ollin Biosciences raises $100M Series A at $500M valuation
Ollin Biosciences: Series A Funding Round
Ollin Biosciences has successfully raised $100M in Series A funding, reaching a valuation of $500M.
Company Overview
Clinical-stage company for vision-threatening disease therapies
Funding Details
The Series A round was led by Deerfield Management, with participation from ARCH Venture Partners.
Company Information
- Headquarters: Austin, TX
- Founded: 2022
- Employees: 70+
- Category: Biotech
Investment
Ollin Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Deerfield Management: Verified investor in Series A
- ARCH Venture Partners: Verified investor in Series A
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started